What Palisade Bio does

Palisade Bio, Inc. (NASDAQ: PALI) is a clinical-stage biopharmaceutical company developing oral therapies for inflammatory bowel disease (IBD). Founded in 2011 as Leading BioSciences and restructured in April 2021 via a reverse merger with Seneca Biopharma, the company is incorporated in Delaware with registered offices in Carlsbad, California and operational offices in Denver, Colorado, and operates with a sub-10-employee team. The lead asset, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed for selective bioactivation in the ileum and colon, targeting moderate-to-severe ulcerative colitis (UC), Crohn's disease (CD), and fibrostenotic Crohn's disease, the last being a population with particularly limited therapeutic options. The U.S. patient populations cited are approximately 1.95 million for UC and 1.63 million for CD, against current IBD market sizes of roughly $7.7 billion (UC) and $8 billion (CD).

The company's core technology is the proprietary PDE4 Prodrug Platform, which produces a colon-selective prodrug with approximately a 6-fold tissue-to-plasma exposure ratio, slower local release, lower peak plasma concentration, and a longer half-life than traditional PDE4 inhibitors. The design is intended to reduce systemic GI and CNS side effects and to enable once-daily dosing versus the twice-daily regimens required by apremilast and roflumilast. Reported clinical results include 100% clinical response (5/5 patients) and 40% remission in a Phase 1b UC study within seven days, 62.8% mean reduction in modified Mayo score, and 47.5% reduction in SES-CD with 40% endoscopic response/remission in fibrostenotic Crohn's disease, with 89 patients treated and no serious adverse events in the Phase 1a program. In June 2026 FDA cleared the IND for PALI-2108, enabling a global Phase 2 ASCENTRA-UC trial of approximately 204 patients across two dose levels (15 mg and 30 mg), with primary efficacy results anticipated in the second half of 2027. Composition-of-matter patents have been granted in Japan (protection to 2041) and Canada.

Palisade Bio is pre-revenue and operates a traditional clinical-stage biotech model: spending on R&D with no product sales and no licensing revenue disclosed, generating $0 today against approximately $11.45 million of trailing-twelve-month negative EBITDA. Following the October 2025 $138 million public offering led by B Group Capital and Columbia Threadneedle Investments, the company held approximately $133 million in cash, providing three to four years of development runway. The go-to-market posture is therefore oriented around investor relations, healthcare-conference participation (TD Cowen, Jefferies, Leerink, Piper Sandler, Needham), scientific congresses (DDW, ECCO, Crohn's & Colitis Congress), and SEC filings rather than commercial sales channels, with the company's reported market capitalization in the $281–301 million range as of June 2026.

Name

Palisade Bio

Legal name

Palisade Bio, Inc.

Website

https://palisadebio.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Palisade Bio is a clinical-stage biopharmaceutical company developing PALI-2108, a once-daily oral PDE4 inhibitor prodrug with colon-selective bioactivation for moderate-to-severe ulcerative colitis and Crohn's disease, including fibrostenotic Crohn's disease.

Ownership category

akta.pro rank

Headquarters

HQ city

Carlsbad

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Drug Development and Commercialization: Palisade Bio is a pre-revenue clinical-stage biopharmaceutical company. The company is developing PALI-2108 through clinical trials with the goal of obtaining FDA approval and commercializing the therapy for inflammatory bowel disease. Revenue will be generated through product sales if the drug receives regulatory approval.

Go-to-market motion1 record

Marketing channels5 records

Core offering

Palisade Bio is a clinical-stage biopharmaceutical company developing PALI-2108, a once-daily oral PDE4 inhibitor prodrug designed for selective bioactivation in the ileum and colon to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company's pipeline is anchored by this lead candidate built on a proprietary PDE4 Prodrug Platform that targets localized drug activation to improve tolerability and pharmacology versus traditional systemic PDE4 inhibitors.

Product overview

Palisade Bio is a clinical-stage biopharmaceutical company advancing targeted oral therapies for inflammatory and fibrotic diseases. The company's portfolio centers on PALI-2108, a once-daily oral PDE4 inhibitor prodrug designed for selective bioactivation in the ileum and colon. The technology is built on the proprietary PDE4 Prodrug Platform, which differentiates traditional PDE4 inhibitors through colon-targeted delivery that improves pharmacokinetics, enhances tolerability by reducing GI side effects, and enables once-daily dosing. The company is advancing toward Phase 2 clinical studies in ulcerative colitis and Crohn's disease.

Differentiator

Problem solved

Functional benefit

Products and services

• PALI-2108 A once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon for targeted treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Currently in Phase 2 clinical development following FDA IND clearance in June 2026.
• PDE4 Prodrug Platform A proprietary technology platform leveraging novel prodrug design to enhance the pharmacology of PDE4 inhibitors, enabling localized delivery in the GI tract with improved tolerability and once-daily dosing potential. Underpins the development of PALI-2108 and serves as the foundation for future pipeline expansion.

Quantifiable outcome

• 100% clinical response achieved in Phase 1b ulcerative colitis trial (5/5 patients)
• +6 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• PSI (Contract Research Organization)coreImplementation/ SI/ Consulting Partner · 29 June 2026Partnered with PSI as the contract research organization to manage execution of the global ASCENTRA-UC Phase 2 clinical trial. PSI will manage trial execution across North America and Europe for approximately 204 patients.
• Iterative Health / Iterative ScopescoreStrategic or Co-development Partner · 2 April 2026Entered into a master services agreement with Iterative Health (also referred to as Iterative Scopes) to assist with patient enrollment for Phase 2 clinical trials. Iterative Health affiliate invested $3 million through purchase of 1,536,885 shares at $1.952 per share (five-day Nasdaq average). The partnership is designed to help accelerate patient recruitment for the ASCENTRA-UC trial of PALI-2108.
• Crohn's & Colitis FoundationcoreStrategic or Co-development Partner · 7 January 2026Received strategic equity investment of up to $500,000 from the Crohn's & Colitis Foundation's IBD Ventures program to support clinical development of PALI-2108 for fibrostenotic Crohn's disease and ulcerative colitis. This represents an endorsement of the company's targeted gut-restricted PDE4 inhibitor approach.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Johnson & Johnson: J&J markets Stelara and Tremfya in IBD and is the entrenched share leader in moderate-to-severe UC/CD, defining the standard-of-care that PALI-2108 must differentiate against in Phase 2.
• Eli Lilly: Lilly is developing mirikizumab (Omvoh) for UC/CD and has been an aggressive acquirer of emerging IBD assets, making it a credible large-pharma comparator and likely strategic counterparty.
• AbbVie: AbbVie's Skyrizi and Rinvoq are leading IBD biologics/oral therapies; Palisade's regulatory lead (Daniel Larkins) and CMC head both came from AbbVie, and AbbVie is the most likely partner/acquirer for differentiated oral IBD assets.
• Pfizer: Pfizer markets etrasimod (Velsipity) for UC and acquired Arena Pharmaceuticals for its IBD pipeline, making it a leading commercial comparator for oral IBD therapies targeting the same gastroenterology prescribers.
• Takeda: Takeda markets Entyvio (vedolizumab) for UC/CD and is one of the largest GI-focused commercial organizations globally, making it directly comparable on go-to-market dynamics for an oral IBD asset.
• Amgen (Otezla/apremilast): Amgen markets Otezla (apremilast), the leading oral PDE4 inhibitor, establishing clinical and commercial precedence for the PDE4 mechanism that PALI-2108 is designed to improve upon via colon-selective bioactivation.
• Bristol Myers Squibb: BMS markets Zeposia (ozanimod), an oral S1P modulator for UC, and Palisade's VP of Clinical Development (James Izanec) previously led registrational programs at BMS, making it a comparable commercial and a likely strategic party.

Emerging players

• Chemomab Therapeutics: Chemomab is a clinical-stage biotech developing therapeutics for inflammatory and fibrotic diseases, overlapping with Palisade's fibrostenotic CD focus; Palisade's CMO previously served as VP of Corporate Development at Chemomab.

Direct peers

• Landos Biopharma: Landos is a clinical-stage biotech developing oral therapeutics for IBD and other inflammatory diseases, directly comparable in stage, modality (oral small molecule), and therapeutic focus; Palisade's Head of Clinical Operations previously led clinical operations at Landos.
• Morphic Holding: Morphic developed oral α4β7 integrin inhibitors for IBD, directly comparable as a clinical-stage biotech advancing an oral, gut-targeted small molecule for UC; Eli Lilly acquired Morphic in 2024, illustrating the acquirer pathway.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/PalisadeBio
• Facebookfacebook.com/PalisadeBio
• LinkedInlinkedin.com/company/palisadebio

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds13 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Palisade Bio